# Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

> **NCT06942416** · PHASE2 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 36 (estimated)

## Conditions studied

- Cervical Cancer
- Neoplasm Recurrence, Local
- Oligometastatic

## Interventions

- **DRUG:** Paclitaxel and Cisplatin/ Carboplatin
- **DRUG:** Iparomlimab and Tuvonralimab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT06942416
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2026-07-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06942416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06942416, "Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06942416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*